Revenue composition centered on the Medical Supply business

「Medical Supply generated ¥509,569 million, accounting for 71.0% of total revenue.」

「Medical Supply benefited from steady performance at SPD facilities that began operating in the previous fiscal year, and also launched SPD projects involving consolidated contracts with multiple hospitals operated by different management entities. As a result, revenue was ¥246,756 million, up 8.7% from the previous interim consolidated accounting period.」

「Medical Supply generated ¥474,919 million, accounting for 70.0% of total revenue.」

「Medical Supply increased revenue as multiple new large-scale SPD facilities began operations, but earnings declined due to the recognition of upfront costs, including labor and equipment expenses associated with their launch, among other factors. As a result, revenue was ¥227,091 million, up 10.3% from the previous interim consolidated accounting period.」

「Medical Supply saw steady operations at new SPD facilities for which contracts were secured in the second half of the previous year. As a result, revenue was ¥316,849 million, up 12.3% year on year.」

「Medical Supply was affected by higher raw material prices and labor costs, while demand for medical supplies recovered as the number of surgical cases increased, among other factors. As a result, revenue was ¥205,922 million, up 11.5% year on year.」

「Medical Supply was affected by higher raw material prices and logistics costs, while demand for medical supplies recovered as the number of surgical cases increased, among other factors. As a result, revenue was ¥101,771 million, up 12.5% year on year, while segment profit (operating profit) was ¥1,245 million, up 26.5% year on year.」

「Medical Supply was affected by higher raw material prices and logistics costs, while new SPD facilities began operating smoothly. Demand for medical supplies also recovered as the number of surgical cases increased, among other factors. As a result, revenue was ¥282,204 million ( up 5.8% year on year for the cumulative period )」

「As a result, revenue was ¥184,681 million, up 6.5% year on year, while segment profit (operating profit) was ¥2,687 million, up 1.6% year on year.」

「As a result, revenue was ¥90,461 million, up 7.3% year on year, while segment profit (operating profit) was ¥984 million, down 7.3% year on year.」

「Revenue comprised ¥99,539 million, or 19.4% of total revenue, from Total Pack Produce; ¥360,635 million, or 70.1%, from Medical Supply; ¥25,247 million, or 4.9%, from Life Care; and ¥28,930 million, or 5.6%, from Dispensing Pharmacies.」

「Revenue was ¥266,757 million, compared with ¥246,656 million in the same cumulative period of the previous year,」

「As a result, revenue was ¥173,368 million, compared with ¥156,029 million in the same cumulative period of the previous year.」

「As a result, revenue was ¥84,322 million, compared with ¥74,912 million in the same cumulative period of the previous year, while segment profit (operating profit) was ¥1,062 million, up 20.3% year on year.」

「Medical Supply generated ¥337,244 million, accounting for 67.8% of total revenue.」

「Medical Supply performed steadily through collaboration within the group, greater operating efficiency and the rollout of infection-control products, despite lower demand associated with fewer medical consultations and the impact of reimbursement price revisions. As a result, revenue was ¥244,447 million, up 1.3% year on year for the cumulative period.」

「Medical Supply performed steadily through collaboration within the group and greater operating efficiency despite the impact of reimbursement price revisions. However, the temporary decline in demand for medical supplies caused by reduced medical consultations and fewer surgeries following the spread of COVID-19 at the beginning of the period continued to affect results. As a result, revenue was ¥154,636 million, down 3.7% year on year for the cumulative period.」

「Medical Supply continued to face difficulty securing profits due to the impact of reimbursement price revisions, but progressed broadly in line with the plan through collaboration within the group and greater operating efficiency, among other factors. As a result, revenue was ¥74,275 million, down 2.1% year on year for the cumulative period.」

「Revenue comprised ¥100,688 million, or 20.8% of total revenue, from Total Pack Produce; ¥325,664 million, or 67.2%, from Medical Supply; ¥23,929 million, or 4.9%, from Life Care; ¥27,050 million, or 5.6%, from Dispensing Pharmacies; and ¥7,062 million, or 1.5%, from Other.」

「Medical Supply performed steadily as a result of efforts to secure new contracts and improve operating efficiency at SPD facilities. As a result, revenue was ¥241,359 million, up 11.9% year on year for the cumulative period.」

「The Medical Supply business performed steadily through collaboration with the Total Pack Produce business, the acquisition of contracts for new SPD facilities, and more efficient operation of SPD facilities. There was also front-loaded demand for consumables ahead of the consumption tax increase. As a result, revenue was ¥160,607 million, up 16.8% from the cumulative second quarter of the previous consolidated fiscal year, and segment profit (operating profit) was ¥2,455 million, up 43.3%.」

「Medical Supply continued to face difficulty securing profits due to the impact of last year's reimbursement price revisions, but progressed broadly in line with the plan through collaboration within the group and greater operating efficiency, among other factors. As a result, revenue was ¥75,882 million, up 11.5% year on year for the cumulative period.」

「Medical Supply faced continued difficulty securing profits from sales of specified insured medical materials due to the impact of reimbursement price revisions, but progressed broadly in line with the plan through greater efficiency in SPD facility operations, among other factors. As a result, revenue was ¥215,681 million, up 7.7% year on year for the cumulative period.」

「Medical Supply progressed broadly in line with the plan, including the smooth launch of new SPD facilities during the previous fiscal year. As a result, revenue was ¥137,553 million, up 6.0% year on year for the cumulative period.」

「Medical Supply progressed broadly in line with the plan, including the smooth launch of new SPD facilities during the previous fiscal year. As a result, revenue was ¥68,078 million, up 7.5% year on year for the cumulative period.」

「Medical Supply generated ¥274,058 million, accounting for 64.4% of total revenue.」

「In the Medical Supply business, the impact of advisory fees associated with the large-scale M&A recorded in the previous fiscal year ended. In addition, operations at the SPD facilities for which contracts were concentrated last year improved and proceeded smoothly, among other factors, resulting in higher revenue and profit. As a result, revenue was ¥200,175 million, up 4.4% from the same period of the previous year on a consolidated cumulative basis, and segment profit (operating profit) was ¥2,701 million, up 50.9%.」

「Medical Supply posted higher revenue and earnings as the impact of advisory fees related to the major M&A transaction recognized in the previous fiscal year ceased, while operations at SPD facilities for which contracts were concentrated last year improved and reached a steady operating level, among other factors. As a result, revenue was ¥129,756 million, up 2.2% year on year for the cumulative period.」

「Medical Supply posted higher earnings as the impact of advisory fees related to the business integration with 小西共和ホールディング株式会社 recognized in the previous fiscal year ceased, while SPD facilities for which contracts were concentrated last year began operating smoothly, among other factors. As a result, revenue was ¥63,335 million, up 0.8% year on year for the cumulative period.」

「Medical Supply posted higher revenue and earnings as a result of the business integration with 小西共和ホールディング㈱, among other factors. As a result, revenue was ¥191,695 million, up 69.3% year on year for the cumulative period.」

「Medical Supply posted a significant increase in revenue despite the impact of revisions to reimbursement prices, owing to the business integration with 小西共和ホールディング株式会社 and the commencement of operations under contract at new SPD facilities, among other factors. As a result, revenue was ¥126,992 million.」

「In the Medical Supply business, revenue increased substantially following the business integration with Konishi Kyowa Holdings Co., Ltd.」

「Medical Supply generated ¥158,227 million, accounting for 51.6% of total revenue, while Total Pack Produce generated ¥102,202 million, accounting for 33.3%.」